Dr. Sadeq Vallian. Phd.

Education:

University of University of Texas [Texas- USA]
Postdoc. , Fellowship in Molecular Medicine, MD Anderson Cancer Center

University of University of London, UK. [London- UK]
Ph.D. , Molecular Medical Genetics, King's College School of Medicine and Dentistry

University of Isfahan Medical Sciences [Isfahan- Iran]
M.Sc. , Clinical Biochemistry

University of Ahwaz [Ahwaz-Iran]
B.Sc. , Genetics

Articles:

1. Garavaglia,B. , **Vallian, S**. , Romito,LM. , Straccia,G. , Capecci, M. , & Invernizzi, F.(2022). AOPEP Variants as A Novel Cause of Recessive

Dystonia: Generalized Dystonia and Dystonia-Parkinsonism. Parkinsonism & Related Disorders 97, 52-56 .

2. Ebrahimi, N. , Rezanejad, H. , Asadi, MH. ,& **Vallian, S**.(2022). LncRNA LOC100507144 Acts as a Novel Regulator of CD44/Nanog/Sox2/miR-302/miR-21 axis in colorectal cancer. BioFactors 48 (1), 164-180.
3. Modarres, P. , Mohamadi Farsani, F, Nekouie, AA. , & **Vallian, S**. (2021). Meta- Analysis of Gene Signatures and Key Pathways Indicates Suppression of JNK Pathway As A Regulator of Chemo-Resistance in AML. Scientific Reports 11 (1), 1- 16.
4. Lin, YC. , Niceta, M. , Muto, V. , Vona, B. , Pagnamenta, AT. , Maroofian, R. , Beetz, C. , **Vallian, S**,& et al.(2021). SCUBE3 loss-of-Function Causes a Recognizable Recessive Developmental Disorder Due to Defective bone morphogenetic protein signaling. The American Journal of Human Genetics 108 (1), 115-133.
5. Najafian- Najafabady, A. , Ebrahimi, N. ,& **Vallian, S**.(2021). rs2682818/MiR-618 is a Novel Marker Associated with an Increased Risk of Breast Cancer in the Iranian Population. Archives of Biological Sciences 73 (4), 457-463.
6. Vahhab, N. , Ebrahimi, N. , Amirmahani, F. , & **Vallian, S**.(2021). Analysis of Polymorphic Markers Located in The HEXA Gene Region Associated With Tay-Sachs Disease. Meta Gene 26, 100772.
7. Chamgordani, LE. , Ebrahimi, N. , Amirmahani, F. ,& **Vallian, S**.(2020). CG/CA Genotypes Represent Nnovel Markers in the NPHS2 Gene Region Associated with Nephrotic Syndrome. Journal of Genetics 99 (1), 1-7.
8. Ebrahimi, N. , Moeinifar, N. , & **Vallian, S**.(2020). rs1542705–67,992,843-1,050,239 Represents A Novel Informative Haplotype At The SMPD1 Locus in The Iranian Population. Meta Gene 25, 100744.
9. Kazemi, A. , **Vallian, S**. (2020). Significant Association of MiR-605 rs2043556 with Susceptibility to Breast Cancer. MicroRNA 9 (2), 133-141.
10. Pourmoshir, N. , Motalleb, G. ,& **Vallian, S**.(2022). hsa-miR-423 rs6505162 is Associated with the Increased Risk of Breast Cancer in Isfahan Central Province of Iran. Cell Journal (Yakhteh) 22 (Suppl 1), 110.
11. Esfahani, MS. , **Vallian, S**.(2019). A Comprehensive Study of Phenylalanine Hydroxylase Gene Mutations in The Iranian Phenylketonuria Patients. European journal of medical genetics 62 (9), 103559.
12. Farsani, FM. **Vallian, S**. , & Ganjalikhany, MR. , Pourmoshir, N. (2019). Characterization of Novel Non-Synonymous Genomic Variants Altering drug Response of DNA Topoisomerase II Alpha. International Journal of Cancer Management 12 (4).

13. Pourmoshir, N. , Farsani, FM. , & **Vallian, S**. (2018). Identification of Novel Estrogen Responsive Genes Differentially Expressed in High-Gradeprostate Cancer Cell Lines. European Journal of Human Genetics, 26, 976-976.
14. Farsani, F.,Ganjalikhany,M.,Pourmoshir,N. , & Vallian, S. (2018). Characterization of Two Novel Non-Synonymous Genomic Variations Altering Drug Response of the DNA Topoisomerase II Alpha in the Iranian Population. European Journal of Human Genetics, 26, 679-680.
15. Dehghanian, F. , Key, M. , & **Vallian, S**. (2018). F1174V Mutation Alters the ALK Active Conformation in Response to Crizotinib in NSCLC: Insight from Molecular Simulations. EUROPEAN JOURNAL OF HUMAN GENETICS 26, 989-990.
16. Shaykholeslam Esfahani,M . , Shaykholeslam Esfahani, E. , & **Vallian, S**.(2018). A novel Compound-Primed Multiplex ARMS-PCR (CPMAP) for Simultaneous Detection of Common PAH gene Mutations. Metabolic Brain Disease 33 (4), 1165-1173.
17. Farsani, FM. , **Vallian, S**.(2018). Variations Related to Resistance of Cancer Cells to Topoisomerase II Alpha Inhibitory Drugs . J Bioinform Proteom Open Access J 2 (1), 000123.
18. Farsani, FM. , Ganjalikhany, MR. , & **Vallian, S**. (2017). Studies on Non-Synonymous Polymorphisms Altering Human DNA Topoisomerase II-alpha Interaction with Amsacrine and Mitoxantrone: An in Silico Approach. Current Cancer Drug Targets 17 (7), 657-668.
19. Dehghanian, F. , Kay, M. , & **Vallian, S**. (2017). F1174V Mutation alters the ALK active Conformation in Response to Crizotinib in NSCLC: Insight from molecular simulations. Journal of Molecular Graphics and Modelling 75, 287-293, 2017.
20. Jazaeri,A . , **Vallian, S**.Association of rs1738074 Polymorphism of TAGAP gene with Susceptibility to Multiple Sclerosis in the Iranian Population . Neuroscience Letters 648, 66-69, 2017.
21. Moghadam, AK., Vallian, J. , & **Vallian, S**.(2017). Molecular Characterization of AIPL1 gene Region in the Iranian Population: Application of Novel Informative Haplotypes and Detection of Mutational Founder Effect. Genes & Genomics, 39 (4), 433-44.
22. Dehbashi, M. , Kamali, E. , & **Vallian, S**.(2017). Comparative Genomics of Human Stem Cell Factor (SCF). Molecular biology research communications 6 (1), 1.
23. Moafi, A. , Vallian, R. , **Vallian, S**, Rahgozar, S. ,Torfenajad, M. , & H Moafi.(2017). The Pros and Cons of the Fourth Revision of Thalassaemia Screening Programme in Iran. Journal of Medical Screening 24 (1), 1-5.